keyword
MENU ▼
Read by QxMD icon Read
search

Dementia treatment

keyword
https://www.readbyqxmd.com/read/29665982/oscillatory-activity-and-cortical-coherence-of-the-nucleus-basalis-of-meynert-in-parkinson-s-disease-dementia
#1
Muhammad Nazmuddin, D L Marinus Oterdoom, J Marc C van Dijk, Jonathan C van Zijl, Anne K Kampman, Gea Drost, Teus van Laar, Martijn Beudel
BACKGROUND: Deep brain stimulation (DBS) of the nucleus basalis of Meynert (NBM) is a new potential treatment for Parkinson's Disease dementia (PDD) and other types of dementia. To get a better understanding of this structure, its local neurophysiological properties and cortical connectivity patterns were studied. METHODS: We simultaneously recorded DBS local field potentials (LFPs) and electroencephalography (EEG) in two patients with PDD. Both patients had DBS electrodes in the internal globus pallidus (GPi) with one or more distal contacts close to or inside the NBM...
March 28, 2018: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/29664058/relationships-between-rapid-eye-movement-sleep-behavior-disorder-and-neurodegenerative-diseases-clinical-assessments-biomarkers-and-treatment
#2
REVIEW
Min Li, Li Wang, Jiang-Hong Liu, Shu-Qin Zhan
Objective: Rapid eye movement sleep behavior disorder (RBD) is characterized by dream enactment and loss of muscle atonia during rapid eye movement sleep. RBD is closely related to α-synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Many studies have investigated the markers of imaging and neurophysiological, genetic, cognitive, autonomic function of RBD and their predictive value for neurodegenerative diseases. This report reviewed the progress of these studies and discussed their limitations and future research directions...
April 20, 2018: Chinese Medical Journal
https://www.readbyqxmd.com/read/29663890/methodologies-related-to-computational-models-in-view-of-developing-anti-alzheimer-drugs-an-overview
#3
Kirtee Baheti, Mayura Ajay Kale
BACKGROUND: Since last two decades, there has been more focus on the development strategies related to Anti-Alzheimer's drug research. This may be attributed to the fact that most of the Alzheimer's cases are still mostly unknown except for a few cases, where genetic differences have been identified. With the progress of the disease, the symptoms involve intellectual deterioration, memory impairment, abnormal personality and behavioural patterns, confusion, aggression, mood swings, irritability Current therapies available for this disease give only symptomatic relief and do not focus on manipulations of biololecular processes...
April 17, 2018: Current Drug Discovery Technologies
https://www.readbyqxmd.com/read/29662677/auto-antibodies-against-p-q-and-n-type-voltage-dependent-calcium-channels-mimicking-frontotemporal-dementia
#4
Kyan Younes, Lauren A Lepow, Cynthia Estrada, Paul E Schulz
The behavioral variant of frontotemporal dementia is usually a sporadic and progressive neurodegenerative disorder. Here, we report the subacute onset of a frontotemporal dementia phenotype with a treatable etiology. The patient has a history of rheumatoid arthritis, episcleritis, and thyroid eye disease on immunosuppressive therapy. He experienced a rapid personality change, including inappropriate behavior, which suggested frontotemporal dementia. Results of imaging and neuropsychological testing also suggested frontotemporal dementia...
2018: SAGE Open Medical Case Reports
https://www.readbyqxmd.com/read/29660988/intervention-helps-family-caregivers-of-people-with-dementia-attain-own-therapy-goals
#5
Gabriele Wilz, Lisette Weise, Christina Reiter, Maren Reder, Anna Machmer, Renate Soellner
INTRODUCTION: Caregiver intervention studies typically assess whether participants attain general goals (eg, improved mental/physical health) but not their own individual goals. We used goal attainment scaling to evaluate whether participants of a telephone intervention based on cognitive behavioral therapy (CBT) attained their personal goals. We also evaluated treatment compliance and implementation. METHODS: A sample of 139 family caregivers of people with dementia received 12 telephone sessions over 6 months...
January 1, 2018: American Journal of Alzheimer's Disease and Other Dementias
https://www.readbyqxmd.com/read/29660938/the-alzheimer-s-disease-assessment-scale-cognitive-subscale-adas-cog-modifications-and-responsiveness-in-pre-dementia-populations-a-narrative-review
#6
Jacqueline K Kueper, Mark Speechley, Manuel Montero-Odasso
The Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) was developed in the 1980s to assess the level of cognitive dysfunction in Alzheimer's disease. Advancements in the research field have shifted focus toward pre-dementia populations, and use of the ADAS-Cog has extended into these pre-dementia studies despite concerns about its ability to detect important changes at these milder stages of disease progression. If the ADAS-Cog cannot detect important changes, our understanding of pre-dementia disease progression may be compromised and trials may incorrectly conclude that a novel treatment approach is not beneficial...
April 11, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29660935/effect-of-cilostazol-on-incident-dementia-in-elderly-men-and-women-with-ischemic-heart-disease
#7
Mi-Young Kim, Yoojin Noh, Sang Joon Son, Sooyoung Shin, Hee-Young Paik, Sukhyang Lee, Yi-Sook Jung
BACKGROUND: Ischemic heart disease (IHD) is associated with cognitive decline and may contribute to an increased risk of dementia. OBJECTIVE: The goal of the present study was to investigate whether cilostazol use is associated with a lower risk of incident dementia in Asian patients with IHD, and whether these effects differed based on sex. METHODS: This retrospective cohort study was performed using the Korean National Insurance Claim Data of the Health Insurance Review and Assessment Service; the duration of the study was from January 1, 2007 to December 31, 2015...
April 11, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29659825/differential-effects-of-14-3-3-dimers-on-tau-phosphorylation-stability-and-toxicity-in-vivo
#8
Katerina Papanikolopoulou, Sofia Grammenoudi, Martina Samiotaki, Efthimios M C Skoulakis
Neurodegenerative dementias collectively known as Tauopathies involve aberrant phosphorylation and aggregation of the neuronal protein Tau. The largely neuronal 14-3-3 proteins are also elevated in the Central Nervous System (CNS) and Cerebrospinal Fluid of Tauopathy patients, suggesting functional linkage. We use the simplicity and genetic facility of the Drosophila system to investigate in vivo whether 14-3-3s are causal or synergistic with Tau accumulation in precipitating pathogenesis. Proteomic, biochemical and genetic evidence demonstrate that both Drosophila 14-3-3 proteins interact with human wild type and mutant Tau on multiple sites irrespective of their phosphorylation state...
April 12, 2018: Human Molecular Genetics
https://www.readbyqxmd.com/read/29659206/effects-of-antipsychotics-on-secular-mortality-trends-in-patients-with-alzheimer-s-disease
#9
René Ernst Nielsen, Jan B Valentin, Annette Lolk, Kjeld Andersen
OBJECTIVE: To investigate secular changes in mortality rates between patients with Alzheimer's disease (AD) and the general population as well as changes in antipsychotic drug treatment and the association between drug treatment and mortality in patients with AD in Denmark during a 12-year study period. METHODS: This nationwide, retrospective cohort study identified all-cause mortality in all Danish patients with incident ICD-10-defined AD from 2000 through 2011...
April 3, 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29659032/at-with-and-beyond-risk-expectations-of-living-with-the-possibility-of-future-dementia
#10
Richard Milne, Ana Diaz, Shirlene Badger, Eline Bunnik, Karine Fauria, Katie Wells
Biomedical research aimed at the development of therapies for chronic and late-onset conditions increasingly concentrates on the early treatment of symptom-less disease. This broad trend is evidenced in prominent shifts in contemporary dementia research. Revised diagnostic criteria and new approaches to clinical trials propose a focus on earlier stages of disease and prompt concerns about the implications of communicating test results associated with the risk of developing dementia when no effective treatments are available...
April 16, 2018: Sociology of Health & Illness
https://www.readbyqxmd.com/read/29659001/state-of-the-science-apathy-as-a-model-for-investigating-behavioral-and-psychological-symptoms-in-dementia
#11
Lauren Massimo, Helen C Kales, Ann Kolanowski
Apathy is one of the most common and pervasive of the behavioral and psychological symptoms of dementia (BPSDs). Apathy has profound consequences for morbidity, mortality, and caregiver burden. Treatment of apathy has been hindered because of poor understanding of the mechanisms underlying this heterogeneous syndrome. Research has demonstrated that apathy is associated with disruption of the frontal-striatal system in individuals with neurodegenerative disease. As with other BPSDs, these neural mechanisms alone do not completely account for the syndrome; individual, caregiver, and environmental factors also contribute to apathy...
April 2018: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29658306/-how-do-they-want-to-know-doctors-perspectives-on-making-and-communicating-a-diagnosis-of-dementia
#12
Cate Bailey, Jemima Dooley, Rose McCabe
Recent drives to facilitate earlier identification of dementia have led to increased memory clinic referrals and diagnoses. This study explored the perspectives of memory clinic doctors on making and delivering diagnoses. Four focus groups were conducted with 13 psychiatrists and two geriatricians in the UK. Transcripts were coded line by line using NVIVO. Thematic analysis identified 39 categories, 18 sub-themes and eight overarching themes. Inter-rater reliability on 31% of the data was 0.89. Increased public awareness of dementia was viewed positively in facilitating access to diagnosis and treatment...
January 1, 2018: Dementia
https://www.readbyqxmd.com/read/29650692/microrna-mediated-therapy-modulating-blood-brain-barrier-disruption-improves-vascular-cognitive-impairment
#13
Kensuke Toyama, Joshua M Spin, Alicia C Deng, Ting-Ting Huang, Ke Wei, Markus U Wagenhäuser, Takuya Yoshino, Huy Nguyen, Joscha Mulorz, Soumajit Kundu, Uwe Raaz, Matti Adam, Isabel N Schellinger, Ann Jagger, Philip S Tsao
OBJECTIVE: There are currently no effective treatments for the prevention of dementia associated with vascular cognitive impairment. MicroRNAs regulate gene expression at the post-transcriptional level and play key roles in vascular disorders. TNFα (tumor necrosis factor-α) regulates blood-brain barrier breakdown through modification of cerebral tight junctions. Here, we sought key TNFα-responsive microRNAs that might influence blood-brain barrier breakdown via cerebral tight junction disruption in vascular cognitive impairment...
April 12, 2018: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/29648983/enhancement-of-brain-d-serine-mediates-recovery-of-cognitive-function-after-tbi
#14
Sigal Liraz-Zaltsman, Barbara Slusher, Dana Atrakchi-Baranes, Kinneret Rosenblatt, Yael Friedman Levi, Efrat Leah Kesner, Alcino J Silva, Anat Biegon, Esther Shohami
Cognitive deficits, especially memory loss, are common and devastating neuropsychiatric sequelae of traumatic brain injury (TBI). The deficits may persist for a long time and may be accompanied by increased risk of developing early onset dementia. Past attempts to reverse the neuropsychological effects of brain injury with glutamate-N-methyl-D-aspartate (NMDA) antagonists failed to show any benefits or worsened the outcome, suggesting activation, rather than blockage, of the NMDA receptor (NMDAR) may be useful in the sub-acute period after TBI and stroke...
March 14, 2018: Journal of Neurotrauma
https://www.readbyqxmd.com/read/29644989/the-palliative-care-in-dementia-context-health-professionals-point-of-view-about-advantages-and-resistances
#15
Sabina Zapponi, Maria Chiara Ascari, Erjona Feracaku, Silvia Masin, Paola Paglia, Roberta Petroccione, Ana Pinzaru, Chiara Foà, Giovanna Artioli, Leopoldo Sarli
BACKGROUND AND AIM: The 38/2010 law has expanded the provision of palliative care to patients with chronic-degenerative diseases. The ISTAT data show that 60% of the dying population is suffering from these diseases and could, according to the literature review, benefit particularly from such treatments. This study investigates the point of view of healthcare professionals, working in the context of dementia, regarding the knowledge and application of palliative care in the field of dementia...
March 26, 2018: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29628039/-economic-impact-of-cognitive-impairment-and-dementia
#16
David Cantarero Prieto
Increased life expectancy has had a corresponding socioeconomic impact due to the ageing population and, among other issues, has increased the incidence of diseases related to cognitive impairment, such as dementia. These changes particularly affect the most developed countries. Any analysis of economic costs aiming to study patients with health problems related to cognitive impairment or dementia should consider the reality of the distinct phases of these disorders and should be conducted from the perspective of the payer, that is, the publicly-funded healthcare system...
June 2017: Revista Española de Geriatría y Gerontología
https://www.readbyqxmd.com/read/29628028/-disorders-associated-with-mild-cognitive-impairment-risk-factors-and-predictors
#17
Manuel Antón Jiménez, José Luis González Guerrero
Traditionally, cognitive impairment has been associated not only with ageing itself but also with concomitant comorbidities that interact in the disease continuum from the prodromic phases. Notable among these are delirium, nutritional alterations, balance and gait, infections and even a progressive incidence of neoplasms. However, with regard to diagnosis and staging, clinicians should perhaps remain especially alert to the possibility of pharmacological iatrogeny, which is not limited to psychopharmacological treatment...
June 2017: Revista Española de Geriatría y Gerontología
https://www.readbyqxmd.com/read/29627920/advances-in-pharmacotherapy-of-late-life-depression
#18
REVIEW
John L Beyer, Kim G Johnson
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT FINDINGS: A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures...
April 7, 2018: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29625597/how-do-we-incorporate-patient-views-into-the-design-of-healthcare-services-for-older-people-a-discussion-paper
#19
Paul R Brocklehurst, Gerald McKenna, Martin Schimmel, Anastassia Kossioni, Katarina Jerković-Ćosić, Martina Hayes, Cristiane da Mata, Frauke Müller
BACKGROUND: Across the European Union costs for the treatment of oral disease is expected to rise to €93 Billion by 2020 and be higher than those for stroke and dementia combined. A significant proportion of these costs will relate to the provision of care for older people. Dental caries severity and experience is now a major public health issue in older people and periodontal disease disproportionately affects older adults. Poor oral health impacts on older people's quality of life, their self-esteem, general health and diet...
April 6, 2018: BMC Oral Health
https://www.readbyqxmd.com/read/29624752/biomarkers-for-cognitive-impairment-in-lewy-body-disorders-status-and-relevance-for-clinical-trials
#20
REVIEW
Andrew Siderowf, Dag Aarsland, Brit Mollenhauer, Jennifer G Goldman, Bernard Ravina
Biomarkers have the potential to improve diagnosis and prognosis, and guide clinical treatment decisions. In research, biomarkers can be used for patient selection and as outcome measures in clinical trials. A range of biochemical and imaging biomarkers are relevant to patients with Lewy body disorders, including PD, PD dementia, and dementia with Lewy bodies. Dopaminergic imaging is used for differential diagnosis of parkinsonian disorders versus tremor disorders without dopamingeric deficits, and also to differentiate dementia with Lewy bodies from Alzheimer's disease...
April 2018: Movement Disorders: Official Journal of the Movement Disorder Society
keyword
keyword
18210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"